STOCK TITAN

Myriad Genetics to Release Fourth Quarter and Full Year 2023 Financial Results on February 27, 2024

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags
Rhea-AI Summary
Myriad Genetics, Inc. announces participation in upcoming healthcare conferences and fourth quarter earnings conference call. Management will provide financial overview, business update, and guidance for 2024. Live webcast available for investors.
Positive
  • None.
Negative
  • None.

Management will also participate in two upcoming healthcare conferences

SALT LAKE CITY, Feb. 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST. The company’s quarterly earnings will be released the same day after the market closes.  

During the call, Myriad management will provide a financial overview and business update of the company’s performance for the fourth quarter and full year 2023. Revenue and earnings guidance for 2024 will also be shared.

A live webcast of the earnings conference call can be accessed on Myriad’s Investor Relations website at investor.myriad.com. To participate in the live conference call via telephone, please register here. Upon registering, a dial-in number and unique PIN will be provided to join the conference call. Following the conference call, an archived webcast of the call will be available at investor.myriad.com.

March Investor Conferences
Management will also be participating in the following investor conferences:

  • The 45th Annual Raymond James & Associates Institutional Investors Conference with a presentation from Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, on March 4, 2024, at 4:35pm EST.
  • The 44th Annual Cowen Health Care Conference with a fireside chat featuring Sam Raha, chief operating officer, and Ben Wheeler, chief financial officer – operations, on March 5, 2024, at 12:50pm EST.

A live and archived webcast of both presentations can be viewed in the investor relations section of Myriad’s website at  investor.myriad.com.

About Myriad Genetics 
Myriad Genetics is a leading genetic testing and precision medicine company dedicated to advancing health and well-being for all. Myriad develops and offers genetic tests that help assess the risk of developing disease or disease progression and guide treatment decisions across medical specialties where genetic insights can significantly improve patient care and lower healthcare costs. For more information, visit www.myriad.com.   

Investor Contact
Matt Scalo
(801) 584-3532
IR@myriad.com

Media Contact
Glenn Farrell
(385) 318-3718
PR@myriad.com


Myriad Genetics, Inc. will hold its fourth quarter earnings conference call on Tuesday, February 27, 2024 at 4:30p.m. EST.

Investors can access the live webcast of the earnings conference call on Myriad's Investor Relations website at investor.myriad.com.

Myriad Genetics, Inc. will participate in the 45th Annual Raymond James & Associates Institutional Investors Conference on March 4, 2024, and the 44th Annual Cowen Health Care Conference on March 5, 2024.

Paul J. Diaz, president and CEO, and Scott Leffler, chief financial officer, will be presenting at the 45th Annual Raymond James & Associates Institutional Investors Conference.

The conferences will feature presentations and fireside chats providing insights into the company's operations and financial performance.

Investors can view the live and archived webcasts of the conference presentations in the investor relations section of Myriad's website at investor.myriad.com.
Myriad Genetics, Inc.

NASDAQ:MYGN

MYGN Rankings

MYGN Latest News

MYGN Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing
US
Salt Lake City

About MYGN

myriad genetics inc., is a leading personalized medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. myriad is focused on three strategic imperatives: maintaining leadership in an expanding hereditary cancer market, diversifying its product portfolio through the introduction of new products and increasing the revenue contribution from international markets. for more information on how myriad is making a difference, please visit the company's website: www.myriad.com.